Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021

作者：Hannah G. Rosenblum, Stephen C. Hadler, Danielle Moulia, Tom T. Shimabukuro, John R. Su, Naomi K. Tepper, Kevin C. Ess, Emily Jane Woo, Adamma Mba‐Jonas, Meghna Alimchandani, Narayan Nair, Nicola P. Klein, Kayla E. Hanson, Lauri Ellen Markowitz, Melinda E. Wharton, Veronica Valentine McNally, Jose Rafael Romero, H. Keipp Talbot, Grace Mee-Jeung Lee, Matthew F. Daley, Sarah A. Mbaeyi, Sara E. Oliver · 发表于：MMWR Morbidity and Mortality Weekly Report · 年份：2021 · DOI：10.15585/mmwr.mm7032e4 · 被引用次数：217 · 研究领域：Peripheral Neuropathies and Disorders、Heparin-Induced Thrombocytopenia and Thrombosis、SARS-CoV-2 and COVID-19 Research

In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for Pfizer-BioNTech and Moderna COVID-19 vaccines, and in February 2021, FDA issued an EUA for the Janssen (Johnson & Johnson) COVID-19 vaccine. After each EUA, the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for vaccine use; currently Pfizer-BioNTech is authorized and recommended for persons aged ≥12 years and Moderna and Janssen for persons aged ≥18 years (1-3). Both Pfizer-BioNTech and Moderna vaccines, administered as 2-dose series, are mRNA-based COVID-19 vaccines, whereas the Janssen COVID-19 vaccine, administered as a single dose, is a recombinant replication-incompetent adenovirus-vector vaccine. As of July 22, 2021, 187 million persons in the United States had received at least 1 dose of COVID-19 vaccine (4); close monitoring of safety surveillance has demonstrated that serious adverse events after COVID-19 vaccination are rare (5,6). Three medical conditions have been reported in temporal association with receipt of COVID-19 vaccines. Two of these (thrombosis with thrombocytopenia syndrome [TTS], a rare syndrome characterized by venous or arterial thrombosis and thrombocytopenia, and Guillain-Barré syndrome [GBS], a rare autoimmune neurologic disorder characterized by ascending weakness and paralysis) have been reported after Janssen COVID-19 vaccination. One (myocarditis, cardiac inflammation) has been reported after Pfizer-BioN...